April 26, 2018 / 6:17 AM / 3 months ago

BRIEF-Karo Pharma Q1 EBITDA rose to SEK 89 mln

April 26 (Reuters) - Karo Pharma AB:

* KARO PHARMA DOUBLES SALES AND EARNINGS IN THE FIRST QUARTER

* Q1 NET SALES AMOUNTED TO MSEK 267.1 (139.3), EQUIVALENT TO AN INCREASE OF 91.7%

* Q1 GROSS MARGIN WAS 56.8% (53.7%) FOR PERIOD

* Q1 EBITDA AMOUNTED TO MSEK 88.7 (43.7) Source text for Eikon: Further company coverage: (Reporting By Stockholm newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below